Economics of lipid lowering with HMG CoA reductase inhibitors

Free article

Comment

D R Illingworth. Clin Cardiol. 1995 Jun.

Free article

. 1995 Jun;18(6):295, 363.

doi: 10.1002/clc.4960180616.

No abstract available

Comment on

Economics of lipid lowering with HMG CoA reductase inhibitors.
Conti CR. Conti CR. Clin Cardiol. 1995 Feb;18(2):60. doi: 10.1002/clc.4960180204. Clin Cardiol. 1995. PMID: 7720290 No abstract available.

Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.
Jolain B, Pettitt D. Jolain B, et al. Clin Ther. 1995 May-Jun;17(3):572-80. doi: 10.1016/0149-2918(95)80123-5. Clin Ther. 1995. PMID: 7585861 No abstract available.
Update on the treatment of hypercholesterolemia, with a focus on HMG-CoA reductase inhibitors and combination regimens.
Ginsberg HN. Ginsberg HN. Clin Cardiol. 1995 Jun;18(6):307-15. doi: 10.1002/clc.4960180605. Clin Cardiol. 1995. PMID: 7664504 Review.
[In process].
Reisdorf S. Reisdorf S. Med Monatsschr Pharm. 2017 Jun;40(6):271-3. Med Monatsschr Pharm. 2017. PMID: 29979855 German. No abstract available.
Cost effectiveness of treatment to National Cholesterol Education Panel (NCEP) targets with HMG-CoA reductase inhibitors. Trial design.
Black D, Davidson M, Koren M, Bakker-Arkema R, Tresh P, McLain R, Smith D, Hunninghake D. Black D, et al. Pharmacoeconomics. 1997 Aug;12(2 Pt 2):278-85. doi: 10.2165/00019053-199712020-00018. Pharmacoeconomics. 1997. PMID: 10170452 Clinical Trial.
Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
Hsu I, Spinler SA, Johnson NE. Hsu I, et al. Ann Pharmacother. 1995 Jul-Aug;29(7-8):743-59. doi: 10.1177/106002809502907-818. Ann Pharmacother. 1995. PMID: 8520093 Review.